“We’re proud of our team for achieving this milestone in our collaboration with Gilead and excited that the hepatitis B candidate is progressing to the clinic,” said
Of note, preclinical data on the hepatitis B vaccine as a potential component for a curative regimen were recently presented at the
The hepatitis B program is one of two independent development programs in HOOKIPA’s collaboration and license agreement with Gilead. The other program aims to develop a novel arenaviral vaccine as a component of a potential functional curative regimen for human immunodeficiency virus (HIV). HOOKIPA is responsible for advancing the investigational HIV therapeutic vaccine through completion of a Phase 1b clinical trial.
About HOOKIPA
Find out more about HOOKIPA online at www.hookipapharma.com.
For further information, please contact:
Media | Investors |
hookipa@instinctif.com | Executive Director - Investor Relations |
+44 (0) 7457 2020 | matthew.beck@hookipapharma.com |
+1 917 209 6886 |
Forward Looking Statements
Certain statements set forth in this press release constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by terms such as “believes,” “expects,” “plans,” “potential,” “would” or similar expressions and the negative of those terms. Such forward-looking statements involve substantial risks and uncertainties that could cause HOOKIPA’s research and clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the drug development process, including HOOKIPA’s programs’ early stage of development, the process of designing and conducting preclinical and clinical trials, the regulatory approval processes, the timing of regulatory filings, the challenges associated with manufacturing drug products, HOOKIPA’s ability to successfully establish, protect and defend its intellectual property, risks relating to business interruptions resulting from the coronavirus (COVID-19) disease outbreak or similar public health crises, the impact of COVID-19 on the enrollment of patients and timing of clinical results, and other matters that could affect the sufficiency of existing cash to fund operations. HOOKIPA undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the company in general, see HOOKIPA’s quarterly report on Form 10-Q for the quarter ended
Investors and others should note that we announce material financial information to our investors using our investor relations website (https://ir.hookipapharma.com/),
![](https://ml.globenewswire.com/media/MzE4NmRjZDctZjY0Mi00NzI5LThhMTAtNjJkZmM4MmVmMmIxLTExNjg0OTM=/tiny/HOOKIPA-Pharma-Inc.png)
2023 GlobeNewswire, Inc., source